Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line

Leukemia Research

Volumn 24, Issue 6, 2000, Pages 519-525

  Ribizzi, Iole ^a   Darnowski, James W ^a   Goulette, Frederick A ^a   Sertoli, Mario Roberto ^a   Calabresi, Paul ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Amifostine; Aminothiol; Apoptosis; Myelodysplasia; p53; Preleukemia

Indexed keywords

AMIFOSTINE; ANNEXIN; DNA FRAGMENT; PROTEIN P53;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; MYELODYSPLASIA; PRIORITY JOURNAL;

AMIFOSTINE; APOPTOSIS; CELL DIVISION; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; RADIATION-PROTECTIVE AGENTS; TUMOR CELLS, CULTURED;

EID: 0033994778     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00007-2     Document Type: Article

References (36)

1. Merchav S., Wagemaker G., Souza L.M., Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant hematopoietic growth factors. Leukemia. 5:1991;340.
2. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndrome. Blood. 86:1997;269.
3. Koeffler H.P. Myelodysplastic syndromes (preleukemia). Semin. Hematol. 23:1986;284.
4. Sheinberg D.A., Maslak P., Weiss M. Myelodysplastic syndrome. De Vita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 5th ed. 1997;2388 Lippincott Raven, Philadelphia, PA.
5. Kantarjian H.M., Keating M.J., Walters R.S., Smith T.L., Cork A., Mc Credie K.B., Freiereich E.J. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J. Clin. Oncol. 4:1986;1748.
6. List A.F., Garewal H.S., Sandberg A.A. The myelodysplastic syndromes: biology and implications for the management. J. Clin. Oncol. 8:1990;1424.
7. Greenberg P.L. Treatment of myelodysplastic syndromes with hematopoietic growth factors (review). Semin. Oncol. 19:1992;106.
8. Schuster M.W., Larson R.A., Thompson J.A., Coiffier B., Bennett J.M., Israel R.J. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multicenter randomized controlled trial. Proc. Am. Soc. Hematol. 76:1990;318a.
9. Stebler C., Tichelli A., Dazzi H., Gratwohl A., Nissen C., Speck B. High-dose recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp. Hematol. 18:1990;1204.
10. Bowen D., Culligan D., Jacobs A. The treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin. Br. J. Haematol. 77:1991;419.
11. Ganser A., Seipelt G., Lindemann A., Ottman O.G., Falk S., Eder M., Hermann F., Becher R., Hoffken K., Buchner T., Klausmann M., Frisch J., Schulz G., Mertelsmann R., Hoelzer D. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood. 76:1990;455.
12. List A.F., Hersh E.M., Taetle R., Rinehart J., Quick D., Neidhart J.A. Phase I/II trial of subcutaneous recombinant interleukin-3 in patients with bone marrow failure. Proc. Am. Assoc. Cancer Res. 33:1992;243a.
13. Gold E.J., Mertelsmann R.H., Itri L.M., Gee T., Arlin Z., Kempin S., Clarkson B., Moore M.A. Phase I clinical trial of 13-cis retinoic acid in myelodysplastic syndromes. Cancer Treat. Rep. 67:1983;981.
14. Mehta A.B., Kumaran T.O., Marshan G.W., McCarthy D.M. Treatment of advanced myelodysplastic syndrome with alfacalcidiol. Lancet. 2:1984;761.
15. Miller K.B., Kim K., Morrison F.S., Winter J.N., Bennett J.M., Neiman R.S., Head D.R., Cassileth P.A., O' connel M.J., Kim K. The evaluation of low dose cytarabine in the treatment of myelodysplastic syndrome: a phase-III intergroup study. Ann. Hematol. 65(4):1992;162.
16. Glover D., Glick J.H., Weiler C., Hurowitz S., Kligerman M.M. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J. Clin. Oncol. 4:1986;584.
17. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roulette B., Homesley M., Belpomme D., Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14:1996;2101.
18. List A.F., Heaton R., Glinsmann-Gibson B., Capizzi R.L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin. Oncol. 23:1996;58.
19. Yuhas J.M., Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat. Rep. 64:1980;57.
20. Yuhas J.M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat. Rep. 63:1979;971.
21. Yuhas J.M., Spellman J.M., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin. Trials. 3:1980;211.
22. List A.F., Heaton R., Glinsmann-Gibson B., Capizzi R. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 12:1998;1596.
23. Amifostine Investigator's Manual. US Bioscience, 1996.
24. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R., Capizzi R. Stimulation of hematopoiesis by Amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364.
25. Bekesi J.G., Banerjee R., Jiang J.D., Roboz J.P., Tarcsafalvi A., Holland J.F., Acs G. Translocation of cytoplasmic antigenic markers in a biphenotypic cell line derived from a patient with myelodysplastic syndrome. Mol. Cell. Differ. 3(2):1995;111.
26. Lotem J., Cragoe E.J., Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood. 78:1991;953.
27. Meier T., Issels R.D. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence of glutathione status of Chinese hamster ovary cells. Pharmacology. 50:1995;489.
28. Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L., Parcharidou A., Dar S., Venugopal P., Borok R., Gezer S., Showel J., Loew J., Robin E., Rifkin S., Alston D., Hernandez B., Shah R., Kaizer H., Gregory S., Preisler H. A paradigm shift in myelodysplastic syndromes. Leukemia. 1D:1996;1648.
29. deCastro C.M., Gockerman J.P., Moore J.O., Hathorn J.W., Hartung C., Misuraca J. Preliminary results of a phase II study of Amifostine for patients with myelodysplastic syndrome. Proc. Am. Soc. Hematol. 90:1997;286b.
30. Ramakrishnan N., Catravas G. N-(2-mercaptoethyil)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J. Immunol. 148:1992;1817.
31. Klimecki W., Heaton R., Glinsmann-Gibson B., List A.F. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Proc. Am. Soc. Hematol. 90:1997;520a.
32. Huang X.K., Gao X.Z., Burke P., Raza A., Preisler H. The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells. Proc. Am. Soc. Clin. Oncol. 16:1997;514a.
33. Treskes M., Boven E., Loosdrecht A.A., Wijffels J.F., Cloos J., Peters G.J., Pinedo H.M., van der Vijgh W.J. Effects of the modulating agent WR-2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur. J. Cancer. 30A(2):1994;183.
34. Green D., Wright A., Shein P.S., Clarke R., Lombardi V.T. WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc. Am. Assoc. Cancer Res. 33:1992;490.
35. Meagher R.C., Rothman S.A., Paul P., Koberna P., Willmer C., Baucco P.A. Purging on small cell lung cancer cells from human bone marrow using ethiofos (WR2721) and light-activated merocyanine 540 phototreatment. Cancer Res. 49:1989;3637.
36. Capizzi R.L., Wang L.M., Taylor C., Paine G., Fernandes D., List A.F. Protracted exposure to amifostine improves the therapeutic index of paclitaxel. Proc. Am. Soc. Clin. Oncol. 15:1996;498.